EP1263775A4 - Peptides de liaison hla et utilisations de ces derniers - Google Patents

Peptides de liaison hla et utilisations de ces derniers

Info

Publication number
EP1263775A4
EP1263775A4 EP00910314A EP00910314A EP1263775A4 EP 1263775 A4 EP1263775 A4 EP 1263775A4 EP 00910314 A EP00910314 A EP 00910314A EP 00910314 A EP00910314 A EP 00910314A EP 1263775 A4 EP1263775 A4 EP 1263775A4
Authority
EP
European Patent Office
Prior art keywords
binding peptides
hla binding
hla
peptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00910314A
Other languages
German (de)
English (en)
Other versions
EP1263775A1 (fr
Inventor
Alessandro Sette
John Sidney
W Martin Kast
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1263775A1 publication Critical patent/EP1263775A1/fr
Publication of EP1263775A4 publication Critical patent/EP1263775A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00910314A 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers Withdrawn EP1263775A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/004655 WO2001062776A1 (fr) 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers

Publications (2)

Publication Number Publication Date
EP1263775A1 EP1263775A1 (fr) 2002-12-11
EP1263775A4 true EP1263775A4 (fr) 2004-10-06

Family

ID=21741082

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00910314A Withdrawn EP1263775A4 (fr) 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers

Country Status (8)

Country Link
EP (1) EP1263775A4 (fr)
JP (1) JP2003524016A (fr)
CN (1) CN1452634A (fr)
AU (1) AU2000232427A1 (fr)
BR (1) BR0017136A (fr)
CA (1) CA2400215A1 (fr)
MX (1) MXPA02008219A (fr)
WO (1) WO2001062776A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535024A (ja) * 1999-06-29 2003-11-25 エピミューン インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの使用
US20030027246A1 (en) * 2000-03-31 2003-02-06 Artur Pedyczak Immunogenic peptides derived from prostate-specific membrane antigen (PSMA) and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
KR20070056042A (ko) 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
EP2657338B1 (fr) * 2005-01-25 2015-07-08 NEC Corporation Peptide de liaison HLA, fragment d'ADN et vecteur de recombinaison codant pour ce peptide de liaison HLA
AU2006259307B2 (en) 2005-06-17 2012-12-20 Mannkind Corporation Epitope analogues
ES2413079T3 (es) * 2005-06-17 2013-07-15 Mannkind Corporation Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral
CN1948333B (zh) * 2005-10-14 2010-12-08 中国人民解放军第二军医大学 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
WO2008031064A1 (fr) * 2006-09-07 2008-03-13 University Of South Florida Peptides hyd1 en tant qu'agents anticancéreux
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
CA2793838C (fr) 2010-03-19 2019-09-17 H. Lee Moffitt Cancer Center & Research Institute, Inc. Inhibiteurs des interactions de l'integrine pour traiter le cancer
US20130183376A1 (en) 2010-09-08 2013-07-18 Saitama Medical University Hepatitis c virus liposome vaccine
WO2015048477A1 (fr) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugués de peptide cyclique et procédés d'utilisation
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
CA3035591A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Compositions immunogenes ciblant des mutations recurrentes du cancer et leurs procedes d'utilisation
CN111655714A (zh) * 2017-11-08 2020-09-11 阿德瓦希斯公司 来自癌症相关蛋白的免疫原性异变肽及其使用方法
DK3773689T5 (da) 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (fr) * 1993-03-05 1994-09-15 Cytel Corporation Peptides se liant a hla-a2.1 et leurs utilisations
WO1997034621A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de fixation de hla-a2.1 et leurs utilisations
WO1998004284A1 (fr) * 1996-07-25 1998-02-05 The Johns Hopkins University Nouveaux genes de l'herpesvirus associe a la maladie de kaposi

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (fr) * 1993-03-05 1994-09-15 Cytel Corporation Peptides se liant a hla-a2.1 et leurs utilisations
WO1997034621A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de fixation de hla-a2.1 et leurs utilisations
WO1998004284A1 (fr) * 1996-07-25 1998-02-05 The Johns Hopkins University Nouveaux genes de l'herpesvirus associe a la maladie de kaposi

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NAYERSINA R ET AL: "HLA A2 RESTRICTED CYTOTOXIC T LYMPHOCYTE RESPONSES TO MULTIPLE HEPATITIS B SURFACE ANTIGEN EPITOPES DURING HEPATITIS B VIRUS INFECTION", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 150, no. 10, 15 May 1993 (1993-05-15), pages 4659 - 4671, XP000609159, ISSN: 0022-1767 *
NIJMAN H W: "IDENTIFICATION OF PEPTIDE SEQUENCES THAT POTENTIALLY TRIGGER HLA-A2.1-RESTRICTED CYTOTOXIC T LYMPHOCYTES", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 23, 1 June 1993 (1993-06-01), pages 1215 - 1219, XP000674255, ISSN: 0014-2980 *
See also references of WO0162776A1 *
SETTE A ET AL: "PEPTIDE BINDING TO THE MOST FREQUENT HLA-A CLASS I ALLELES MEASURED BY QUANTITATIVE MOLECULAR BINDING ASSAYS", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 31, no. 11, 1994, pages 813 - 822, XP000603774, ISSN: 0161-5890 *

Also Published As

Publication number Publication date
BR0017136A (pt) 2003-02-25
CN1452634A (zh) 2003-10-29
MXPA02008219A (es) 2005-06-30
CA2400215A1 (fr) 2001-08-30
AU2000232427A1 (en) 2001-09-03
EP1263775A1 (fr) 2002-12-11
JP2003524016A (ja) 2003-08-12
WO2001062776A1 (fr) 2001-08-30

Similar Documents

Publication Publication Date Title
EP1578432A4 (fr) Peptides de liaison hla et utilisations de ces derniers
EP1064022A4 (fr) Peptides de liaison de hla et leurs applications
ATA898A (de) Snowboard - einstiegsbindung
DE69827307D1 (de) Turbolader
FR2785543B1 (fr) Exosomes modifies et utilisations
EP0888120A4 (fr) Peptides de liaison aux hla et utilisations
PT975638E (pt) Epothilons modificados nas cadeias laterais
ID20391A (id) Susunan blok-bantalan tekan untuk turbocharger
DE69810184D1 (de) Drosselvorrichtung
DE59911754D1 (de) Abgasturbolader
DE59904511D1 (de) Abgasturbolader
DE60107990D1 (de) Foliebehandlungsvorrichtung und Umwickelvorrichtung
EP1401791A4 (fr) Composes de liaison de cyclophiline non peptidique et leurs utilisations
DE10084580T1 (de) Kompressionshandschuh
DE69927299D1 (de) Imitator-zellulosebindungsdomäne
AT500208B8 (de) Turbolader
DE69706521D1 (de) Modifiziertes inulin
EP1343819A4 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
DE50105970D1 (de) Verstemmstempel und verwendung desselben
PT1218388E (pt) Ligantes electronicamente afinados
DE69827522D1 (de) Bindevorrichtung
DE50108296D1 (de) Abgasturbolader
EP1313505A4 (fr) Peptides de fixation de hla et leurs utilisations
EP1299327A4 (fr) Polypeptides phosphoryles et utilisations correspondantes
FI20000656L (fi) Hydraulijärjestelmä ja siihen sovitettava vaimennin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040819

17Q First examination report despatched

Effective date: 20070213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070824